PromiCell

Executive Summary

PromiCell is a private, Phase 3-stage cell and gene therapy company headquartered in San Diego, California, dedicated to transforming cancer care through advanced CAR-T and TCR therapies. Founded in 2005, the company has spent over two decades pioneering innovative approaches to harness the immune system against malignancies. With a focus on delivering life-changing solutions, PromiCell's lead programs are now in late-stage clinical development, targeting significant unmet needs in oncology. The company's robust research pipeline and commitment to groundbreaking science position it as a potential leader in the next generation of adoptive cell therapies. As a private entity, PromiCell is not yet publicly traded, but its progress toward regulatory milestones and potential commercialization could drive substantial value upon eventual IPO or partnership.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 CAR-T therapy pivotal trial data readout65% success
• Q4 2026Regulatory submission (BLA) for lead CAR-T candidate60% success
• Q1 2027Early-stage TCR therapy IND filing80% success